[1] [2] The pivotal SUSTAIN trials, which evaluated semaglutide for type 2 diabetes, and the STEP trials for weight management did not identify cold intolerance as a statistically significant adverse event
Novo Nordisk, which used to be the unchallenged king of GLP-1 weight-loss shots, has blown its lead over the past year, as evidenced by the Danish companys serious guidance cut last week
The STAT Clinics give patients the opportunity to have their diagnoses managed right away, and literature shows that the clinics diagnostic and treatment model improves outcomes for patients
In addition, GLP-1 treatments showed an improvement on left ventricular function as well as reducing the levels of the brain natriuretic peptide (BNP), which is a hormone associated with heart failure
This combination slows glucose absorption and prevents the sharp spikes and crashes